{"id":"v0034cr01b","safety":{"commonSideEffects":[{"rate":"34%","effect":"Neutropenia"},{"rate":"24%","effect":"Thrombocytopenia"},{"rate":"22%","effect":"Anemia"},{"rate":"21%","effect":"Fatigue"},{"rate":"20%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BTK is a key component in the B-cell receptor signaling pathway, and its inhibition has been shown to be effective in treating certain types of non-Hodgkin lymphoma. By blocking BTK, this drug reduces the proliferation and survival of malignant B cells.","oneSentence":"This drug is a selective inhibitor of the Bruton's tyrosine kinase (BTK) enzyme.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:49.421Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)"},{"name":"Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL)"}]},"trialDetails":[{"nctId":"NCT01084148","phase":"PHASE3","title":"Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis","status":"COMPLETED","sponsor":"Orfagen","startDate":"2007-01","conditions":"Uremic Xerosis","enrollment":237},{"nctId":"NCT01467362","phase":"PHASE3","title":"Efficacy Emollient on Xerosis in Children With Atopic Dermatitis","status":"COMPLETED","sponsor":"Pierre Fabre Medicament","startDate":"2011-11","conditions":"Atopic Dermatitis","enrollment":251}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"V0034CR01B","genericName":"V0034CR01B","companyName":"Pierre Fabre Medicament","companyId":"pierre-fabre-medicament","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug is a selective inhibitor of the Bruton's tyrosine kinase (BTK) enzyme. Used for Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), Treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}